Genotype-guided use of oral antithrombotic therapy: A pharmacoeconomic perspective

Personalized Medicine

Volumn 11, Issue 2, 2014, Pages 223-235

  Sweezy, Taylor ^a   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

apixaban; clopidogrel; dabigatran; oral anticoagulant; oral antiplatelet; pharmacogenomics; prasugrel; rivaroxaban; ticagrelor; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; DABIGATRAN; DABIGATRAN ETEXILATE; MULTIDRUG RESISTANCE PROTEIN 1; PRASUGREL; RIVAROXABAN; TICAGRELOR; VITAMIN K EPOXIDE REDUCTASE; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COMPLICATION; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; GENETIC POLYMORPHISM; GENOTYPE; HEALTH CARE COST; HUMAN; PATIENT CARE; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESOURCE ALLOCATION; REVIEW; THROMBOEMBOLISM; UNITED STATES;

EID: 84899494036     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.13.106     Document Type: Review

References (82)

1. Wang L, Weinshilboum RM. Pharmacogenomics: Candidate gene identification, functional validation and mechanisms. Hum. Mol. Genet. 17(R2), R174-R179 (2008
2. Graf M, Needham D, Teed N, Brown T. Genetic testing insurance coverage trends: A review of publicly available policies from the largest US payers. Pers. Med. 10(3), 235-243 (2013
3. Hirsh J, Dalen J. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119, S8-S21 (2001
4. Melnikova I. The anticoagulants market. Nat. Rev. Drug Discov. 8(5), 353-354 (2009
5. Rettie AE, Korzekwa KR, Kunze KL et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol. 5(1), 54-59 (1992
6. Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352(22), 2285-2293 (2005
7. Yuan H-Y, Chen J-J, Lee MT et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet. 14(13), 1745-1751 (2005
8. Verschuren JJ, Trompet S, Wessels JA et al. A systematic review on pharmacogenetics in cardiovascular disease: Is it ready for clinical application? Eur. Heart J. 33(2), 165-175 (2012
9. Schalekamp T, De Boer A. Pharmacogenetics of oral anticoagulant therapy. Curr. Pharm. Design 16(2), 187-203 (2010
10. Linder MW, Looney S, Adams JE 3rd et al. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J. Thromb. Thrombolysis 14(3), 227-232 (2002
11. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353, 717-719 (1999
12. Di Nisio M, Middeldorp S, Büller HR. Direct thrombin inhibitors. N. Engl. J. Med. 353(10), 1028-1040 (2005
13. Paré G, Eriksson N, Lehr T et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 127(13), 1404-1412 (2013
14. Cavallari LH, Shin J, Perera MA. Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy 31(12), 1192-1207 (2011
15. Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: Beyond strictly antiplatelet actions. Blood 109(6), 2285-2292 (2007
16. Coughtrie MW, Gilissen RA, Shek B et al. Phenol sulphotransferase SULT1A1 polymorphism: Molecular diagnosis and allele frequencies in Caucasian and African populations. Biochem. J. 337(Pt 1), 45-49 (1999
17. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 361(24), 2342-2352 (2009
18. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365(10), 883-891 (2011
19. Graff J, Harder S. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin. Pharmacokinet. 52(4), 243-254 (2013
20. New oral anticoagulant drugs dabigatran etexilate and rivaroxaban: Influence of genetic factors in healthy volunteers.http://clinicaltrials.gov/ ct2/show/NCT01627665
21. Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365(11), 981-992 (2011
22. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 115(1), 15-20 (2010
23. Wang L, Raghavan N, He K et al. Sulfation of O-demethyl apixaban: Enzyme identification and species comparison. Drug Metab. Dispos. 37(4), 802-808 (2009
24. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 367(9510), 606-617 (2006
25. Marín F, González-Conejero R, Capranzano P, Bass TA, Roldán V, Angiolillo DJ. Pharmacogenetics in cardiovascular antithrombotic therapy. J. Am. Coll. Cardiol. 54(12), 1041-1057 (2009
26. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J. Am. Coll. Cardiol. 46(9), 1705-1709 (2005
27. Anderson JL, Adams CD, Antman EM et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 123(18), e426-e579 (2011
28. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7), 494-502 (2001
29. Bhatt DL, Bertrand ME, Berger PB et al. Meta-Analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J. Am. Coll. Cardiol. 39(1), 9-14 (2002
30. Gladding P, Panattoni L, Webster M, Cho L, Ellis S. Clopidogrel pharmacogenomics: Next steps: A clinical algorithm, gene-gene interactions, and an elusive outcomes trial. J. Am. Coll. Cardiol. 3(10), 995-1000 (2010
31. Gladding P, White H, Voss J et al. Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: A dose-escalation study. JACC Cardiovasc. Interv. 2(11), 1095-1101 (2009
32. Price MJ, Murray SS, Angiolillo DJ et al. Influence of genetic polymorphisms on the effect of high-And standard-dose clopidogrel after percutaneous coronary intervention: The GIFT (Genotype Information and Functional Testing) study. J. Am. Coll. Cardiol. 59(22), 1928-1937 (2012
33. Seip RL, Duconge J, Ruaño G. Implementing genotype-guided antithrombotic therapy. Future Cardiol. 6(3), 409-424 (2010
34. Hulot JS, Bura A, Villard E et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108(7), 2244-2247 (2006
35. Grosdidier C, Quilici J, Loosveld M et al. Effect of CYP2C19. *2 and . *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. Am. J. Cardiol. 111(7), 985-990 (2013
36. Tello-Montoliu A, Jover E, Marín F et al. Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome. Rev. Esp. Cardiol. (Engl. Edition). 65(3), 219-226 (2012
37. Scott SA, Sangkuhl K, Stein CM et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin. Pharmacol. Ther. 94(3), 317-323 (2013
38. Mega JL, Close SL, Wiviott SD et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: A pharmacogenetic analysis. Lancet 376(9749), 1312-1319 (2010
39. Taubert D, von Beckerath N, Grimberg G et al. Impact of P-glycoprotein on clopidogrelabsorption. Clin. Pharmacol. Ther. 80(5), 486-501 (2006
40. Ancrenaz V, Daali Y, Fontana P et al. Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability. Curr. Drug Metab. 11(8), 667-677 (2010
41. Tantry US, Bliden KP, Wei C et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: The ONSET/OFFSET and RESPOND genotype studies. Circ. Cardiovasc. Genet. 3(6), 556-566 (2010
42. Wallentin L, James S, Storey RF et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the PLATO trial. Lancet 376(9749), 1320-1328 (2010
43. Parodi G, Valenti R, Bellandi B. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients. J. Am. Coll. Cardiol. 61(15), 1601-1606 (2013
44. Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab. Dispos. 38(9), 1514-1521 (2010
45. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001-2015 (2007
46. Rehmel J, Eckstein J, Farid N. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab. Dispos. 34(4), 600-607 (2006
47. Mega JL, Close SL, Wiviott SD et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119(19), 2553-2560 (2009
48. Kelly RP, Close SL, Farid NA et al. Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. Brit. J. Clin. Pharmacol. 73(1), 93-105 (2012
49. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045-1057 (2009
50. King JT, Tsevat J, Lave JR, Roberts MS. Willingness to pay for a quality-Adjusted life year: Implications for societal health care resource allocation. Med. Decision Making 25(6), 667-677 (2005
51. Weinstein MC. Recent developments in decision-Analytic modelling for economic evaluation. Pharmacoeconomics 24(11), 1043-1053 (2006
52. Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan. 21(July), 402-408 (2006
53. Epstein RS, Moyer TP, Aubert RE et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J. Am. Coll. Cardiol. 55(25), 2804-2812 (2010
54. Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J. Gen. Intern. Med. 24(5), 656-664 (2009
55. Anderson JL, Horne BD, Stevens SM et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 125(16), 1997-2005 (2012
56. van Schie RM, Wadelius MI, Kamali F et al. Genotype-guided dosing of coumarin derivatives: The European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 10(10), 1687-1695 (2009
57. Joo J, Geller N, French B. Prospective alpha allocation in the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Clin. Trials 7(5), 597-604 (2010
58. Do E, Lenzini P, Eby C. Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): Rationale and study design. Pharmacogenomics J. 12(5), 417-424 (2011
59. European Pharmacogenetics of anticoagulant therapy-warfarin (EU-PACT).http://clinicaltrials.gov/show/NCT01119300
60. Clarification of optimal anticoagulation through genetics (COAG).www.clinicaltrials.gov/ct2/show/NCT00839657
61. Genetics informatics trial (GIFT) of warfarin to prevent DVT.http://clinicaltrials.gov/show/NCT01006733
62. Cost-effectiveness of genotype guided treatment with antiplatelet drugs in STEMI patients: Optimization of treatment (POPGenetics).http:// clinicaltrials.gov/show/NCT01761786
63. Kimmel SE, French B, Kasner SE et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N. Engl. J. Med. 369(24), 2283-2293 (2013
64. Pirmohamed M, Burnside G, Eriksson N et al. A randomized trial of genotype-guided dosing of warfarin. N. Engl. J. Med. 369(24), 2294-2303 (2013
65. Hillman MA, Wilke RA, Yale SH et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin. Med. Res. 3(3), 137-145 (2005
66. Anderson JL, Home BD, Stevens SM et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 27(116), 2563-2570 (2007
67. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: A prospective randomized controlled study. Clin. Pharmacol. Ther. 83(3), 460-470 (2007
68. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann. Intern. Med. 150(2), 73-83 (2009
69. You JH, Tsui KK, Wong RS, Cheng G. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy. Clin. Pharmacol. Ther. 86(5), 540-547 (2009
70. Patrick AR, Avorn J, Choudhry NK. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ. Cardiovasc. Qual. Outcomes 2(5), 429-436 (2009
71. You JH, Tsui KK, Wong RS, Cheng G. Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. PLoS ONE 7(6), e39640 (2012
72. Shah S V, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 123(22), 2562-2570 (2011
73. Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am. J. Cardiol. 110(6), 845-851 (2012
74. Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 44(6), 1676-1681 (2013
75. Lee S, Mullin R, Blazawski J, Coleman CI. Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. PLoS ONE 7(10), e47473 (2012
76. Kamel H, Easton JD, Johnston SC, Kim AS. Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. Neurology 79(14), 1428-1434 (2012
77. Reese ES, Daniel Mullins C, Beitelshees AL, Onukwugha E. Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy 32(4), 323-332 (2012); erratum: 32(6), 581 (2012
78. Panattoni L, Brown PM, Te Ao B, Webster M, Gladding P. The cost-effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: A New Zealand evaluation. Pharmacoeconomics 30(11), 1067-1084 (2012
79. Lea RA, Roberts RL, Green MR, Kennedy MA, Chambers GK. Allele frequency differences of cytochrome P450 polymorphisms in a sample of New Zealand Maori. N. Z. Med. J. 121(1272), 33-37 (2008
80. Crespin DJ, Federspiel JJ, Biddle AK, Jonas DE, Rossi JS. Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: A cost-effectiveness analysis. Value Health 14(4), 483-491 (2011
81. Stedtfield R, Tourlousse D, Seyrig G et al. Gene-Z: A device for point of care genetic testing using a smartphone. Lab. Chip. 12(8), 1454-1462 (2012
82. Dobson M, Galvin P, Barton D. Emerging technologies for point-of-care genetic testing. Expert Rev. Mol. Diagn. 7(4), 359-370 (2007